Novare Pharmaceuticals Announces Research Agreement With Lawson Health Research Institute

• The agreement includes the creation of an incubator focused on potential treatments for major diseases such as breast cancer and lung fibrosis using the modulation of RHAMM.
• The incubator will be led by Dr. Eva Turley, a globally recognized leader in RHAMM research and a Professor in the Department of Oncology at Western University, who also serves as Chief Scientist for Novare.

BOSTON & LONDON, Ontario--(BUSINESS WIRE)--Novare Pharmaceuticals, which is developing therapeutic products that modulate the Receptor for Hyaluronan-Mediated Motility (RHAMM), is pleased to announce a research and licensing agreement with Lawson Health Research Institute that includes the creation of an incubator focused on potential treatments for major diseases, including arthritis, breast cancer, and lung fibrosis.

“The Lawson and Novare partnership serves as an inspiring and much-needed model for the development of early-stage technologies from academic health research organizations”

The Novare research incubator in the city of London, Ontario, Canada is being led by Dr. Eva Turley, Chief Scientist at Novare and a global leader in RHAMM research as a Professor in the Department of Oncology, Western University, and Scientist in the London Regional Cancer Program, London Health Sciences Centre. She is joined by Dr. Leonard Luyt, who is an Assistant Professor in the same university oncology department as well as a Principal Investigator in the cancer program, and who is assisting with the development of proprietary peptides being used in Novare’s drug development programs.

“Our agreement with Lawson allows us to bring together the top minds in the field of RHAMM, providing us with a unique opportunity to go after major disease states,” said Michael Delmage, Chief Executive Officer of Novare. “Combining Novare’s business acumen in drug development, regulatory approval and quality assurance with the translational science expertise, infrastructure and facilities at Lawson will help to ensure that this research focuses on finding benefits for real patients fighting real diseases.”

Novare is investigating the modulation of RHAMM, a cellular protein that helps to regulate cell movement and stem cell differentiation. Therapeutic products that control RHAMM aim to safely and selectively stimulate cell differentiation as well as reduce destructive inflammation and scarring inherent in diseases such as lung fibrosis and arthritis. Other potential applications include breast cancer, scarless healing for burns and post-surgical wounds, and the regeneration of breast tissue after a mastectomy.

“The Lawson and Novare partnership serves as an inspiring and much-needed model for the development of early-stage technologies from academic health research organizations,” said Dr. Turley. “The partnership with Novare helps Lawson fulfill its mandate to translate healthcare discoveries from the lab to the patient.”

Lawson Health Research Institute is the research institution of London Health Sciences Centre and St. Joseph’s Health Care London. The group of more than 1,600 investigators, technicians and support staff collaborate to advance scientific knowledge related to healthcare topics such as aging, cancer and neurological disorders.

“Novare’s funding is critical in the current environment of reduced traditional funding sources for validation of early-stage research and discovery,” said Kirk Brown, Manager for Business Development at Lawson. “The partnership with Novare has also allowed us to create new jobs for our community, bolstering our efforts to create economic, as well as medical, benefits from our research.”

About Novare Pharmaceuticals

Novare Pharmaceuticals develops therapeutic products that modulate RHAMM, a natural protein that alters migratory cell behavior and promotes cell differentiation. Novare is at the forefront of finding treatments for a wide variety of inflammatory conditions, including Bronchopulmonary Dysplasia (BPD) in premature infants and arthritis, to fibrotic diseases, such as Idiopathic Pulmonary Fibrosis (IPF). RHAMM modulation can also play a role in controlling breast cancer and additionally can provide a means of tissue engineering that promotes the regeneration of breast tissue after a mastectomy. The company is a subsidiary of Allied Minds (LSE:ALM), an innovative U.S. science and technology development and commercialization company based in Boston. More information about the company can be found on its website, www.novarepharma.com

About Lawson Research Institute

The Lawson Health Research Institute is located in London, Ontario, Canada and is the research institute of London Health Sciences Centre and St. Joseph’s Health Care London. As one of the largest hospital-based research institutes in Canada, Lawson is committed to furthering scientific knowledge to advance health care around the world. Further information on Lawson can be found at www.lawsonresearch.com

About Allied Minds

Allied Minds (LSE:ALM) is an innovative U.S. science and technology development and commercialization company. Operating since 2006, Allied Minds forms, funds, manages and builds products and businesses based on innovative technologies developed at leading U.S. universities and federal research institutions. Allied Minds serves as a diversified holding company that supports its businesses and product development with capital, central management and shared services. More information about the Boston-based company can be found at www.alliedminds.com

Allied Minds Forward-Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company’s future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risk and uncertainties described in the risk factors included in the company’s regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Prospectus Rules, the Listing Rules and the Disclosure and Transparency Rules, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.